Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR).
Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR).
复制标题
在卵巢癌病例中，HER-2/NEU表达是不表达卵泡刺激激素受体（FSHR）的阴性预后剂。
DOI：
10.1186/1757-2215-6-6
复制
发表时间：
2013-01-22
影响因子：
4
通讯作者：
Dian D
中科院分区：
文献类型：
--
作者：
Heublein S;Vrekoussis T;Mayr D;Friese K;Lenhard M;Jeschke U;Dian D
抗HER-2治疗成功地用于HER-2过表达乳腺癌患者，并显着涉及其生存率。在这些有希望的结果的基础上，还测试了抗HER-2治疗方案作为上皮卵巢癌（EOC）的一种选择。但是，已知HER-2信号通过G蛋白偶联受体（GPCR）调节。由于卵巢癌的常见GPCR是FSH受体（FSHR），因此我们研究了HER-2在根据其FSHR状态分层的患者中的预后意义。
这项研究总共包括153名EOC患者。使用标准方案评估了HER-2阳性。有趣的是，HER-2仅是那些未表达FSHR的患者的整体生存率差的独立预后标记。这既不适用于整个面板，也不适用于FSHR共表达。
因此，我们得出的结论是，HER-2只有在FSHR负EOC案例中才能是负预后剂。因此，通过根据其FSHR表达状态对EOC患者进行分层，我们引入了诊断方案，以有效选择EOC患者，这很可能对抗HER-2治疗有反应。在选择最有可能受益于抗HER-2治疗的患者方面，这种观察可能具有临床重要性。
Anti-Her-2 treatment is successfully administered to Her-2 overexpressing breast cancer patients and significantly implicates upon their survival. Building on these promising results, anti-Her-2 treatment protocols were tested as an option for epithelial ovarian cancer (EOC) as well. However Her-2 signalling is known to be modulated by G-protein coupled receptors (GPCR). Since a common GPCR in ovarian cancer is the FSH receptor (FSHR), we investigated the prognostic significance of Her-2 in patients that had been stratified according to their FSHR status. A total number of 153 EOC patients were included in this study. Her-2 positivity was assessed using a standard protocol. Intriguingly Her-2 turned out to be an independent prognostic marker for poor overall survival only in those patients that did not express FSHR. This did neither apply for the whole panel nor in case of FSHR co-expression. We thus conclude that Her-2 can be a negative prognosticator only in FSHR negative EOC cases. Hence by stratifying EOC patients according to their FSHR expression status, we introduce a diagnostic protocol to effectively select EOC patients that would most probably respond to anti-Her-2 treatment. This observation could be of clinical importance in terms of selecting the patient that would most likely benefit from anti-Her-2 treatment.
登录
查看更多内容
影响因子：
9.7
作者：
HUNG, MC;ZHANG, X;SHI, DR
通讯作者：
SHI, DR
影响因子：
45.3
作者：
Bookman, MA;Darcy, KM;Horowitz, IR
通讯作者：
Horowitz, IR
DOI：
10.1097/01.pgp.0000152026.39268.57
发表时间：
2005-04-01
影响因子：
2.4
作者：
Lee, CH;Huntsman, DG;Gilks, CB
通讯作者：
Gilks, CB
影响因子：
51.1
作者：
Gianni, Luca;Dafni, Urania;Bell, Richard
通讯作者：
Bell, Richard
影响因子：
4.8
作者：
Maudsley, S;Pierce, KL;Luttrell, LM
通讯作者：
Luttrell, LM